AbbVie Inc.
Close on Nov 2, 2026Market cap $510.41BP/E 81.6Yield 2.30%
AbbVie Restasis [legacy through FY24] by Quarter
Restasis (cyclosporine ophthalmic emulsion) [legacy through FY24] — Worldwide net revenues ($M) ($M)
AbbVie Restasis [legacy through FY24]: $114M in Q4 2024, down 10.9% from a year earlier. No newer figure appears in the documents we track.
Where the Q4 2024 figure comes from
Calculated from reported figures: Q4 = full year (10-K) − nine months (10-Q)
Source: Form 10-K (filed 2025-02-14) ↗
Reported in Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Key Product Revenues.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Restasis (cyclosporine ophthalmic emulsion) [legacy through FY24] — Worldwide net revenues ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q4 2024 | Dec 31, 2024 | 114 | -10.9% | Form 10-K (filed 2025-02-14) ↗ |
| Q3 2024 | Sep 30, 2024 | 21 | -82.1% | Form 10-Q (filed 2024-11-04) ↗ |
| Q2 2024 | Jun 30, 2024 | 32 | -67.7% | Form 10-Q (filed 2024-08-07) ↗ |
| Q1 2024 | Mar 31, 2024 | 57 | -38.0% | Form 10-Q (filed 2024-05-03) ↗ |
| Q4 2023 | Dec 31, 2023 | 128 | +16.4% | Form 10-K (filed 2025-02-14) ↗ |
| Q3 2023 | Sep 30, 2023 | 117 | -17.6% | Form 10-Q (filed 2024-11-04) ↗ |
| Q2 2023 | Jun 30, 2023 | 99 | -41.1% | Form 10-Q (filed 2024-08-07) ↗ |
| Q1 2023 | Mar 31, 2023 | 92 | -62.6% | Form 10-Q (filed 2024-05-03) ↗ |
| Q4 2022 | Dec 31, 2022 | 110 | -69.8% | Form 10-K (filed 2025-02-14) ↗ |
| Q3 2022 | Sep 30, 2022 | 142 | -55.5% | Form 10-Q (filed 2023-11-06) ↗ |
| Q2 2022 | Jun 30, 2022 | 168 | -48.6% | Form 10-Q (filed 2023-08-07) ↗ |
| Q1 2022 | Mar 31, 2022 | 246 | -12.1% | Form 10-Q (filed 2023-05-05) ↗ |
| Q4 2021 | Dec 31, 2021 | 364 | +5.8% | Form 10-K (filed 2024-02-20) ↗ |
| Q3 2021 | Sep 30, 2021 | 319 | +6.7% | Form 10-Q (filed 2022-11-04) ↗ |
| Q2 2021 | Jun 30, 2021 | 327 | +127.1% | Form 10-Q (filed 2022-08-04) ↗ |
| Q1 2021 | Mar 31, 2021 | 280 | – | Form 10-Q (filed 2022-05-06) ↗ |
| Q4 2020 | Dec 31, 2020 | 344 | – | Form 10-K (filed 2023-02-17) ↗ |
| Q3 2020 | Sep 30, 2020 | 299 | – | Form 10-Q (filed 2021-11-02) ↗ |
| Q2 2020 | Jun 30, 2020 | 144 | – | Form 10-Q (filed 2021-08-02) ↗ |
| Q1 2020 | Mar 31, 2020 | 0 | – | Form 10-Q (filed 2021-05-07) ↗ |
| Q4 2019 | Dec 31, 2019 | 0 | – | Form 10-K (filed 2022-02-18) ↗ |
| Q3 2019 | Sep 30, 2019 | 0 | – | Form 10-Q (filed 2020-11-04) ↗ |
| Q2 2019 | Jun 30, 2019 | 0 | – | Form 10-Q (filed 2020-08-04) ↗ |
Breakdown
What makes up restasis [legacy through FY24]
- Restasis (cyclosporine ophthalmic emulsion) [legacy through FY24] — U.S. net revenues ($M)102 · Q4 2024
- Restasis (cyclosporine ophthalmic emulsion) [legacy through FY24] — International net revenues ($M)12 · Q4 2024
- Restasis (cyclosporine ophthalmic emulsion) [legacy through FY24] — Worldwide reported growth YoY (%)-11.3% · Q4 2024
- Restasis (cyclosporine ophthalmic emulsion) [legacy through FY24] — Worldwide operational (constant-currency) growth YoY (%)-10.9% · Q4 2024
Cite this data
StockData. (2026). AbbVie Restasis [legacy through FY24] ($M), quarterly Q2 2019–Q4 2024 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/restasis-ww
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.